Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis

Affiliations

¹ Unit of Infectious Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna 40138, Italy. Electronic address: marina.tadolini@unibo.it.
² Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK; Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
³ World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Tradate, Italy.

Comment

Marina Tadolini et al. Lancet Infect Dis. 2018 May.

. 2018 May;18(5):480-481.

doi: 10.1016/S1473-3099(18)30106-3. Epub 2018 Feb 13.

¹ Unit of Infectious Diseases, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna 40138, Italy. Electronic address: marina.tadolini@unibo.it.
² Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, UK; Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
³ World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Tradate, Italy.

No abstract available

Comment on

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P. Ferlazzo G, et al. Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13. Lancet Infect Dis. 2018. PMID: 29452942